27 assets in Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia

Therapeutic assets addressing Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dexasone Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CCC (53)
Cpx-351 Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Children's Oncology Group	P1/2	CCC (48)
Fludarabine Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Children's Oncology Group	P1/2	CCC (48)
Hydrocortisone Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Children's Oncology Group	P1/2	CCC (48)
Imgn632 Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Children's Oncology Group	P1/2	CCC (48)
Mercaptopurine Anhydrous Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
Mesna Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
Methotrexate Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Children's Oncology Group	P1/2	CCC (48)
Obi 3424 Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	SWOG Cancer Research Network	P1/2	CCC (48)
Pegfilgrastim Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
Prednisolone Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Children's Oncology Group	P1/2	CCC (48)
Prednisone Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
Rituximab Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
(+)-Vincristine Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
Vincristine Sulfate Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	ECOG-ACRIN Cancer Research Group	P1/2	CCC (48)
Capivasertib Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CC (45)
Cyclophosphamide Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CC (45)
Cytarabine Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CC (45)
Dasatinib Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CC (45)
Decitabine Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CC (45)
Navitoclax Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CC (45)
Ruxolitinib Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CC (45)
Trametinib Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CC (45)
Venetoclax Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CC (45)
Filgrastim-Sndz Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	M.D. Anderson Cancer Center	P1/2	CC (43)
Sti-6129 Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	M.D. Anderson Cancer Center	P1	CC (43)
Tagraxofusp-Erzs Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia	M.D. Anderson Cancer Center	P1/2	C (33)